TY  - CONF

T1  - 1111P A randomised phase II study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)

JO  - Annals of Oncology

UR  - http://dx.doi.org/10.1016/j.annonc.2023.09.2245

PY  - 2023/10/01

AU  - Gupta A

AU  - Matin RN

AU  - Dayimu A

AU  - Nobes J

AU  - Board RE

AU  - Payne M

AU  - Rao AR

AU  - Fusi A

AU  - Danson S

AU  - Eccles BK

AU  - Carser J et al

ED  - 

DO  - DOI: 10.1016/j.annonc.2023.09.2245

PB  - Elsevier BV

VL  - 34

SP  - S669

EP  - S670

Y2  - 2024/09/19

ER  -